Parenteral Drug Association Meeting: Risk Based Inspections
Published: Feb 11, 2010
The UK Chapter of the Parenteral Drug Association (PDA) is hosting a networking seminar on Risk Based Inspections, on 16th March 2010, at MedImmune Cambridge with keynote speaker Ian Thrussell of the MHRA. Ian Thrussell will discuss how the risk-based inspection program has evolved, the implications of the new system for industry, lessons learnt so far, plus how the system may develop in the future. Industry speakers will also discuss their experience of the Risk Based Inspection program with the group. Then participants will have the chance to join in an open forum discussion with Ian Thrussell and their peers to discuss how the risk based assessment is working. This meeting provides the opportunity to understand how the MHRA’s risk based inspections program is developing, what changes this brought to the inspection program and to question an MHRA expert on how best to prepare for this inspections program. It is aimed at those working within: Risk Management, QA, QC, Manufacturing, R&D and Consulting. Registration for this half day event is now open. Please contact Alison Smith for a booking form (email@example.com). Booking forms need to be received by early March as places are limited and this is expected to be a very popular event. The Parenteral Drug Association (PDA) is the leading global provider of science, technology and regulatory information and education for the pharmaceutical and biopharmaceutical community. Founded in 1946 as a nonprofit organization, PDA is committed to developing scientifically sound, practical technical information and resources to advance science and regulation through the expertise of its more than 11,000 members worldwide.